Zobrazeno 1 - 9 of 9 pro vyhledávání: '"Madlyn Ferraro"'
1
A phase I study evaluating ibritumomab tiuxetan (Zevalin®) in combination with bortezomib (Velcade®) in relapsed/refractory mantle cell and low grade B-cell non-Hodgkin lymphoma
Autor: Dominic T. Moore, Madlyn Ferraro, Peggy Ford, Andre Goy, Tatyana Feldman, Anne W. Beaven, Anastasia Ivanova, Thomas C. Shea, Judith Smith
Publikováno v: Leukemia & Lymphoma. 53:254-258
Proteasome inhibitors may inhibit DNA repair of radiation-induced strand breaks and adducts thereby making the combination of radioimmunotherapy and bortezomib a promising approach. Preclinical models demonstrate additive/synergistic effects from com
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::fdb6322747201de261f72b84c715c1aa
https://doi.org/10.3109/10428194.2011.608445
Zobrazit plný text záznamu
2
TBCRC 001: randomized phase II study of cetuximab in combination with carboplatin in stage IV triple-negative breast cancer
Autor: P. Kelly Marcom, E. Burrows, Hope S. Rugo, Andres Forero-Torres, Charles M. Perou, Lisa A. Carey, Erica L. Mayer, Minetta C. Liu, Anna Maria Storniolo, Eric P. Winer, Philip S. Bernard, Francisco J. Esteva, Anastasia Ivanova, Katherine A. Hoadley, Wing Keung Chiu, Cynthia X. Ma, Madlyn Ferraro, Mothaffar F. Rimawi, Timothy J. Hobday, Antonio C. Wolff
Publikováno v: Journal of clinical oncology : official journal of the American Society of Clinical Oncology, vol 30, iss 21
Purpose Epidermal growth factor receptor (EGFR) is a targetable receptor frequently overexpressed in basal-like breast cancer, which comprises most triple-negative breast cancers (TNBCs), the only subtype without established targeted therapy. Patient
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::f6110eded2be74f450d626fc38980b9a
https://pubmed.ncbi.nlm.nih.gov/22665533
Zobrazit plný text záznamu
3
Radiosensitization of chemotherapy-refractory, locally advanced or locally recurrent breast cancer with trastuzumab: a phase II trial
Autor: Janet K. Horton, Dominic T. Moore, David W. Ollila, Madlyn Ferraro, Jan Halle, Carolyn I. Sartor, Lisa A. Carey
Publikováno v: International journal of radiation oncology, biology, physics. 76(4)
Purpose Trastuzumab (Herceptin), an anti-human epidermal growth factor receptor 2 (HER2) antibody, has been shown to be an effective radiosensitizer in preclinical studies. The present Phase II trial evaluated trastuzumab plus radiotherapy in patient
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::599297d5d15e165d4a32cbef66745611
https://pubmed.ncbi.nlm.nih.gov/19560883
Zobrazit plný text záznamu
5
Results of a Phase I Study of Vorinostat In Combination with Pegylated Liposomal Doxorubicin and Bortezomib In Patients with Relapsed/Refractory Multiple Myeloma
Autor: Cristina Gasparetto, Madlyn Ferraro, Peter M. Voorhees, Kristy L. Richards, Jennifer MacLean, John S. Strader, Dominic T. Moore, Robert Z. Orlowski, Keren Osman, Reynaldo Garcia, David D. Hurd, Diane Winans
Publikováno v: Blood. 116:1955-1955
Abstract 1955 Introduction: The histone deacetylase inhibitor vorinostat has additive to synergistic activity in combination with anthracyclines and proteasome inhibitors in preclinical models of multiple myeloma (MM). We therefore sought to evaluate
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::6975e59eda93f501b9bc72cc03e3f5db
https://doi.org/10.1182/blood.v116.21.1955.1955
Zobrazit plný text záznamu
7
Assays of circulating tumor cells and outcome in the triple-negative breast cancer trial TBCRC001
Autor: MC Liu, EP Winer, Lisa A. Carey, Dominic T. Moore, Francisco J. Esteva, Andres Forero, Hope S. Rugo, John W. Park, Madlyn Ferraro, Antonio C. Wolff, Timothy J. Hobday, Nancy E. Davidson, Erica L. Mayer, Paul K. Marcom, Janet H. Scott, Cynthia X. Ma, Anna Maria Storniolo
Publikováno v: Cancer Research. 69:6048
Abstract #6048 Introduction. Basal-like breast cancer (BBC) has low expression of ER, PR, and HER2, and is often called triple negative (TN) BrCa. TBCRC 001 is a multicenter randomized phase II study of cetuximab (C) alone or combined with carboplati
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::a050ca9dda8cc436bcb2f4ae598e57c3
https://doi.org/10.1158/0008-5472.sabcs-6048
Zobrazit plný text záznamu
8
A Phase I Study of Bortezomib (Velcade®) Plus 90yttrium Labeled Ibritumomab Tiuxetan (Zevalin®) in Patients with Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma (NHL)
Autor: Andre Goy, Anastasia Ivanova, Dominic T. Moore, Thomas C. Shea, Madlyn Ferraro, Judy Smith, Anne W. Beaven, Peggy Ford, Tatyana Feldman
Publikováno v: Blood. 112:4944-4944
Background: Radio-immunoconjugates such as 90Yttrium labeled ibritumomab tiuxetan (IT) have been shown to have significant activity in the treatment of patients with low grade NHL. Bortezomib (Bz), the first proteasome inhibitor, has also demonstrate
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::b27081a0eed561341540bfb69c717337
https://doi.org/10.1182/blood.v112.11.4944.4944
Zobrazit plný text záznamu
9
TBCRC 001: EGFR inhibition with cetuximab added to carboplatin in metastatic triple-negative (basal-like) breast cancer
Autor: E. Burrows, EP Winer, Lisa A. Carey, Charles M. Perou, Hope S. Rugo, William J. Irvin, Xiaping He, Paul K. Marcom, Madlyn Ferraro
Publikováno v: Journal of Clinical Oncology. 26:1009-1009
1009 Background: Basal-like breast cancer (BBC) has low expression of ER, PR, and HER2, and is thus often called triple negative (TN). Preclinical studies suggest that BBC depend on EGFR/HER1 for proliferation. TBCRC 001 is a multicenter randomized p
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::a87ee33f2f6f22c235f1b42c3e8968df
https://doi.org/10.1200/jco.2008.26.15_suppl.1009
Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání

Omezení vyhledávání
Plný text Recenzováno Digitální knihovna AV ČR
Zdroje